The value of biomarkers in diagnosis and treatment of heart failure with preserved ejection fraction retention
10.3760/cma.j.cn114452-20230907-00122
- VernacularTitle:生物标志物在射血分数保留心力衰竭诊疗中的价值
- Author:
Zhenlu ZHANG
1
Author Information
1. 武汉亚洲心脏病医院检验科武汉 430022
- Keywords:
Heart failure;
Heart failure with ejection fraction preservation;
Biomarkers;
Biomarkers of "crosstalk" between heart-liver-lung-kidney
- From:
Chinese Journal of Laboratory Medicine
2023;46(12):1224-1234
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure with preserved ejection fraction (HFpEF)is a heterogeneous disease, and as a systemic syndrome, it presents different clinical course and prognosis. Currently, HF is not effective in its treatment. For the diagnosis and treatment of HFpEF, at present and in the future, should we focus more on the biomarkers involving the "crosstalk" between organs such as heart-liver-lung-kidney, based on the good application of existing commonly used markers, such as high-sensitivity troponin and BNP/NT-proBNP.
